Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis

References

• Hoffman BJ. Sensitivity of sulfadiazine resembling acute dissem-inated lupus erythematosus. Arch Derm Syphilol. 1945;51:190–2.
   Google Scholar
• Costa M, Said N, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor a agents. Semin Arthritis Rheum. 2008;37:381–7.
   Google Scholar
• Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis. Arthritis Rheum. 2000;43:405–13.
   PubMed Web of Science ®Google Scholar
• Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol. 2008;20:35–9.
   PubMed Web of Science ®Google Scholar
• Morrow JD, Schroeder HA, Perry HM. Studies on the control of hypertension by Hyphex. Toxic reactions and side-effects. Cir-culation. 1953;8:829–39.
   Google Scholar
• Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am. 1994;20:61–84.
   PubMed Web of Science ®Google Scholar
• Bernstein RM, Egerton-Vernon J, Webster J. Hydralazine-induced cutaneous vasculitis. Br Med J. 1980;280:156–7.
   PubMed Web of Science ®Google Scholar
• Ludmerer KM, Kissane JM. Renal failure dyspnea and anemia in a 57 year old woman. Am J Med. 1981;71:876–86.
   PubMedGoogle Scholar
• Björck S, Westberg G, Svalander C, Mulec H. Rapidly progres-sive glomerulonephritis after hydralazine. Lancet. 1983;2:42.
   Google Scholar
• Nässberger L, Johansson AC, Björck S, Sjöholm AG. Antibodies to neutrophil granulocyte myeloperoxidase and elastase: auto-immune responses in glomerulonephritis due to hydralazine treatment. J Intern Med. 1991;229:261–5.
   Google Scholar
• Peacock A, Weatherall D. Hydralazine-induced necrotizing vas-culitis. Br Med J. 1981;282:1121–2.
   PubMedGoogle Scholar
• Finlay AY, Statham B, Knight AG. Hydralazine-induced necro-tizing vasculitis. Br Med J. 1981;282:1703–4.
   Google Scholar
• Weiser G, Forouhar FA, White W. Hydralazine hoarseness. A new appearance of drug-induced systemic lupus erythematosus. Arch Intern Med. 1984;144:2271–2.
   Google Scholar
• Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J. 1984;289:410–2.
   PubMed Web of Science ®Google Scholar
• Ihle BU, Whitworth JA, Dowling JP, Kincaid-Smith P. Hydral-azine and lupus nephritis. Clin Nephrol. 1984;22:230–8.
   PubMedGoogle Scholar
• Doherty M, Maddison PJ, Grey RH. Hydralazine induced lupus syndrome with eye disease. Br Med J. 1985;290:675.
   Google Scholar
• Björck S, Svalander C, Westberg G. Hydralazine-associated glomerulonephritis. Acta Med Scand. 1985;218:261–9.
   PubMedGoogle Scholar
• Mehrotra TN, Raka MS, Mithal R, Mehrotra A. Hydralazine induced necrotizing vasculitis. J Assoc Physicians India. 1986;34:502–3.
   PubMedGoogle Scholar
• Martinez-Vea A, Ferrer I, Carcia C, Mayayo E, Oliver JA, Ri-chart C. Systemic vasculitis resembling periarteritis nodosa in the lupus-like syndrome induced by hydralazine. Am J Nephrol. 1987;7:71–3.
   Google Scholar
• Sturman SG, Kumararatne D, Beevers DG. Fatal hydralazine-induced systemic lupus erythematosus. Lancet. 1988;2:1304.
   Google Scholar
• Almroth G, Eneström S, Hed J, Samuelsson I, Sjöström P. Autoantibodies to leukocyte antigens in hydralazine-associated nephritis. J Intern Med. 1992;231:37–42.
   PubMed Web of Science ®Google Scholar
• Cambridge G, Wallace H, Bernstein RM, Leaker B. Autoanti-bodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis. Rheumatology. 1994;33:109–14.
   Google Scholar
• Short AK, Lockwood CM. Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. Q J Med. 1995;88:775–83.
   Google Scholar
• Norris JH, Leeds J, Jeffrey RF. P-ANCA positive renal vasculitis in association with renal cell carcinoma and prolonged hydral-azine therapy. Ren Fail. 2003;25:311–4.
   Google Scholar
• Thakrar M, Pendharkar SR, Penney CJ, Hirani N. Hydralazine-induced pulmonary hemorrhage associated with a lupus antico-agulant. Chest. 2007;132:7225–35.
   Google Scholar
• Franssen C, Gans R, Kallenberg CK, Hagelken C, Hoortje S. Disease spectrum of patients with antineutrophil cytoplasmic autoantibodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase auto-antibodies. J Intern Med. 1998;224: 209–16.
   Google Scholar
• Vasoo S. Drug induced lupus: an update. Lupus. 2006;15:757–61.
   PubMed Web of Science ®Google Scholar
• Sen D, Isenberg D. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus. 2003;12:651–8.
   PubMed Web of Science ®Google Scholar
• Burlingame RW, Rubin RL. Drug-induced anti-histone autoan-tibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest. 1991;88:680–90.
   PubMed Web of Science ®Google Scholar
• Portanova J, Arndt R, Kotzin BL. Anti-histone antibodies in idiopathic and drug-induced lupus recognize distinct intrahistone regions. J Immunol. 1987;138:446–51.
   Google Scholar
• Torffvit Thysell H, Nässberger L. Occurrence of autoantibodies directed against myelooxidase and elastase in patients treated with hydralazine and presenting with glomerulonephritis. Hum Exp Toxicol. 1994;13:563–7.
   PubMedGoogle Scholar
• Reidy TJ, Upshaw JDJ, Chesney TM. Propylthiouracil-induced vasculitis: Fatal case. South Med J. 1982;75:1297–8.
   Google Scholar
• Pillinger M, Staud R. Wegener's Granulomatosis in a patient receiving Propylthiouracil for Grave's disease. Semin Arthritis Rheum. 1998;28:124–9.
   PubMed Web of Science ®Google Scholar
• Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science. 1994;266:810–3.
   Google Scholar
• Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison vasculitides. Arthritis Res Ther. to hydralazine resembling systemic rheumatoid arthritis. Am J Med. with idiopathic ANCA 2005;7:R1072–81.
   Google Scholar
• Perry HM. Late toxicity lupus erythematosus or 1973;54:58–72.
   Google Scholar
• Vizjak A, Rott T, Koselj-Kajtna M, Roman B, Kaplan-Pavlovcic S, Ferluga D. Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with cor-relation to ANCA antigen specificity. Am J Kidney Dis. 2003;41:539–49.
   Google Scholar